palmitoylethanolamide.com.au
HomeResearchFlavia 2022

Why Use Nutraceutical Strategies for the Irritable Bowel Syndrome?

Flavia di Michele. Curr Med Chem. 2022;29(12):2075-2092.

ReviewHumans

Design
Review
Subjects
Not stated in the abstract
Dose used in the study
Not stated in the abstract
Duration
Not stated in the abstract
What was measured
Why nutraceuticals might help irritable bowel syndrome, and how probiotics, prebiotics, synbiotics, butyrate, palmitoylethanolamide and colostrum are each thought to work

What the authors reported

These compounds act through several mechanisms, including restoring the microbiota, strengthening the gut barrier, and immunomodulatory, anti-inflammatory and antinociceptive actions. Published data suggest they improve IBS symptoms with good safety and tolerability, though the author says clinical trials so far are limited and more are needed.

Limits of this study

A narrative review with no new data and no trial numbers for palmitoylethanolamide. Funding and conflicts not stated in the abstract.

Source

PubMed 34533437 · doi:10.2174/0929867328666210917115255

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.